Moderna (MRNA) Hits 52-Week High Before Q3 Earnings

Moderna stock jumped 13% to $258.38 before its Q3 earnings, lifted by a WHO Ebola vaccine nod and cancer-vaccine momentum, extending a 600%-plus gain this year.

Lead

Why Did Moderna Stock Jump Ahead of Earnings?

Moderna rose because two separate catalysts arrived within days of each other, ahead of a quarterly report that investors expect to show weaker sales.

The first was infectious disease. The World Health Organization's Technical Advisory Group recommended that Moderna's Ebola vaccine candidate, mRNA-1469, advance to a Phase 2/3 trial. The recommendation allows development to continue but does not establish efficacy. It nonetheless broadens the pipeline beyond respiratory vaccines, which have been the company's main source of revenue since the pandemic.

The second was oncology. Early clinical data on mRNA-2808, a multiple myeloma candidate, was selected for an oral presentation at the American Society of Hematology annual meeting. The selection added to a run of positive pipeline news that has reshaped how the market values the company.

What Is Driving Moderna's 600% Rally This Year?

Moderna's 2026 rally rests mainly on intismeran autogene, a personalized mRNA cancer vaccine developed with Merck (NYSE: MRK). In August, the companies reported that the therapy, given alongside Merck's Keytruda, reduced the risk of recurrence and spread in high-risk melanoma. The Phase 3 INTerpath-001 trial enrolled more than 1,100 patients whose tumors had been surgically removed.

Moderna shares rose by as much as 160% in a single session on that result and continued climbing through the autumn. Overall-survival data have not been reported, and the vaccine is not approved. The valuation therefore reflects expectations of regulatory success and commercial scale rather than current earnings.

The move has also drawn capital toward biotech company stocks more broadly, particularly those with late-stage oncology programs.

What Do Investors Expect From Moderna's Q3 Report?

The consensus forecast is for Q3 revenue of roughly $890 million, down about 12% from $1.02 billion a year earlier. It also calls for a loss of about $1.10 per share, against a loss of $0.51 in the same quarter of 2025. Other estimates put the loss as high as $1.37 per share and revenue near $889 million.

Moderna has beaten the consensus earnings estimate in seven of its last eight quarters. Sales of its respiratory vaccines remain seasonal and under pressure, so the report is unlikely to move the valuation on its own. Investors will focus on:

• Updated full-year revenue and cost guidance.
• Cash position and operating expense trends.
• Timing of regulatory filings for intismeran.
• Enrollment and design details for the Ebola Phase 2/3 program.
• Progress on the autoimmune and rare-disease pipeline.

Valuation and Market Context

At more than $102 billion, Moderna is valued at a high multiple of sales that are falling year over year. The gap between current revenue and market value is the clearest sign that the stock is priced on pipeline outcomes. Large moves around earnings are common for biotech issuers, and a stock that has risen 13% in one session can move sharply in either direction on guidance or trial commentary.

The rally has also lifted sentiment toward the wider biotech etf and healthcare etf categories, which hold large oncology and vaccine developers. Merck, as Moderna's partner and the maker of Keytruda, has a direct stake in the outcome. Keytruda faces patent expiration later this decade, which gives the combination therapy added strategic weight for Merck.

Outlook

Moderna enters today's report at a 52-week high, with a WHO-backed Ebola program, a Phase 3 cancer vaccine win, and a new myeloma presentation behind the stock's 2026 run. The quarter's financial results are expected to show lower revenue and a wider loss. Guidance, cash runway and the regulatory path for intismeran are likely to set the stock's direction in the sessions ahead, and overall-survival data remain the largest open question for the cancer franchise.